Masts Cell and Ulcerative Colitis

 Masts Cell and Ulcerative Colitis

A new study has shown that a common receptor, FceRI-a, located on mast cells and basophils may be instrumental in the development of ulcerative colitis. In addition, the researchers found that a probiotic, L. planterum can be used as treatment against the immune consequences of activation of these receptors. It was found that these bacteria produce lactate acid, which acts on the NLRP6 inflammasome, which improves intestinal lining integrity. Ulcerative colitis patients exhibit elevated mass cells, IgE and FceRI receptor levels. Researchers have shown that antibodies against this receptor provides a good diagnostic biomarker for development of UC. They also showed that animals lacking antibodies to this receptor showed less UC symptoms with DSS challenge in receptor-deficient mice, and the microbiome was abundant in Lactobacillus. This shows a shows a protective effect of this bacteria on colitis.
Ulcerative colitis is considered an autoimmune condition and activation of mast cells through the a-subunit of the FceRI receptor seems to be the trigger in ulcerative colitis. This study supports previous studies that showed activation of mast cells are important for the pathophysiology of ulcerative colitis.

www.nature.com/articles/s41522-024-00563-z
May be an image of text
Like
Comment
Share

Comments